Observational studyAsian journal of andrology2026
Predicting the upgrading of the International Society of Urological Pathology Grade Group in nonclinically significant prostate cancer: a multicenter observational study.
Observational study in Asian journal of andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to explore the predictors of International Society of Urological Pathology (ISUP) Grade Group (GG) upgrading in nonclinically significant prostate cancer (non-csPCa) biopsy specimens guided by transrectal ultrasound (TRUS) following radical prostatectomy (RP). A retrospective analysis was conducted on clinical data from 231 patients who underwent TRUS-guided biopsy and RP between January 2018 and December 2023. Univariate and multivariate logistic regression analyses were employed to identify independent predictors of postoperative ISUP GG upgrading. The diagnostic efficiency of these predictors was evaluated using receiver operating characteristic (ROC) curves. Additionally, ROC analysis was used to compare the predictive performance of different positive target (PT) imaging methods across prostate volume (PV) subgroups. The study included 111 (48.1%) patients in the GG concordance group and 120 (51.9%) patients in the GG upgrading group. Univariate analysis revealed that PV, prostate-specific antigen density, Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1), magnetic resonance imaging (MRI) PT, contrast-enhanced ultrasound (CEUS) PT, and clinical T stage significantly influenced GG upgrading (all P < 0.05). Multivariate logistic regression revealed PV (OR = 0.974; 95% CI: 0.955-0.994; P = 0.010), MRI PT (OR = 3.902; 95% CI: 1.507-10.102; P = 0.005), and CEUS PT (OR = 2.280; 95% CI: 1.073-4.845; P = 0.032) as independent predictors. The prediction model demonstrated the highest diagnostic performance (area under the receiver operating characteristic curve [AUC] = 0.738, P < 0.001). MRI PT showed superior predictive efficacy compared with CEUS PT in patients with a PV <30.13 ml. In conclusion, PV, CEUS PT, and MRI PT were identified as independent predictors of postoperative ISUP GG upgrading. The predictive model exhibited the best overall performance, and compared with CEUS PT, MRI PT demonstrated greater predictive accuracy for smaller prostates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.